<DOC>
	<DOCNO>NCT02089386</DOCNO>
	<brief_summary>Treat Barrett 's esophagus ( BE ) patient tamoxifen Barrett 's metaplasia measure change Barrett 's esophagus appearance endoscopy histology well change SOX2 CDX2 .</brief_summary>
	<brief_title>Tamoxifen Treat Barrett 's Metaplasia</brief_title>
	<detailed_description>Treat Barrett 's esophagus ( BE ) patient tamoxifen determine effect Barrett 's metaplasia measure change Barrett 's esophagus appearance endoscopy histology . Tamoxifen treatment may induce SOX2 expression , decrease CDX2 promote esophageal stem cell activity , lead regression Barrett 's metaplasia . To test hypothesis , conduct prospective , pilot study patient BE , without high grade dysplasia , treat tamoxifen assess change appearance BE endoscopy histology well change SOX2/CDX2 ratio indicative improvement BE metaplasia</detailed_description>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Biopsyproven Barrett 's esophagus nondysplastic low grade dysplasia . At least 18 year age . ECOG performance status ≤ 2 Normal bone marrow organ function define : Absolute neutrophil count ≥1,500/mcl Platelets ≥ 100,000/mcl AST ( SGOT ) /ALT ( SGPT ) ≤1.5 x IULN Serum creatinine within normal institutional limit le low limit normal institutional limit ; creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign IRB approve write informed consent document . Prior history esophageal cancer . Prior history current use tamoxifen antiestrogen therapy . A history allergic reaction attribute compound similar chemical biologic composition tamoxifen . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant and/or breastfeeding . Female patient must negative urine pregnancy test within 14 day study entry . Known HIVpositivity combination antiretroviral therapy potential pharmacokinetic interaction tamoxifen . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Taking medication know affect drug metabolism via CYP3A4 , CYP2C9 , CYP2D6 pathways . History blood clot ( i.e . pulmonary embolism , DVTs ) . Concurrent use anticoagulant ( i.e . Coumadin/warfarin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>